Fulcrum Therapeutics, Inc. (FULC) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US3596161097
Fulcrum Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -84.77 m USD |
| EBIT | -74.88 m USD |
| Net income | -74.88 m USD |
| Diluted EPS – continuing operations | -1.18 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
More stocks
- SCG Decor PCL (SCGD.BK)
- DreamTech Co Ltd (192650.KS)
- Chia Ta World Co Ltd (2033.TW)
- Liaoning SG Automotive Group Co Ltd (600303.SS)
- Immix Biopharma, Inc. (IMMX)
- Toyota Caetano (SCT.LS)
- Deutsche Real Estate (DRE2.F)
- Izertis Sa (IZER.MC)
- Anhui Chaoyue Environmental Protection Technology Co. Ltd. (301049.SZ)
- AerSale Corp (ASLE)
- Nak Sealing Technologies Corp (9942.TW)
- Tomocube Inc (475960.KQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.